GS-CA1

GS-CA1 is an experimental **small-molecule HIV capsid inhibitor** developed by **Gilead Sciences** as an early research predecessor to lenacapavir. It binds directly to the **HIV-1 capsid** at a capsid protein interface and potently suppresses viral replication at picomolar concentrations in cell-based systems. Mechanistically, GS-CA1 interferes with multiple capsid-dependent steps of the viral life cycle, including **uncoating, nuclear import of viral DNA, particle production, and ordered capsid assembly**, while stabilizing the viral core. It has been described as a potential **long-acting injectable** antiviral approach for **HIV-1 infection**, but based on the provided context it appears to have remained a research-stage compound rather than a marketed medicine.

Brand names

Sunlenca

Other names

lenacapavilenacapavir